Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Europäische Union - Deutsch - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklid-bildgebung - therapeutische radiopharmazeutika - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Europäische Union - Deutsch - EMA (European Medicines Agency)

provepharm sas - methylthioniniumchlorid - methämoglobinämie - alle anderen therapeutischen produkte - akute symptomatische behandlung von durch arzneimittel und chemische produkte induzierter methämoglobinämie. methylthioninium chloride proveblue ist indiziert bei erwachsenen, kindern und jugendlichen (im alter von 0 bis 17 jahre alt).

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

unither pharmaceuticals - ambroxol hydrochloride - lösung zum einnehmen - 30 mg/5 ml - ambroxol hydrochloride 6 mg/ml - ambroxol

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

synthon - tamsulosin hydrochloride - hartkapsel mit veränderter wirkstofffreisetzung - 0,4 mg - tamsulosin hydrochloride 0.4 mg - tamsulosin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela - levamisole hydrochloride - pulver zum einnehmen - levamisole hydrochloride 800 mg/g - levamisole - schwein

Europäische Union - Deutsch - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pharma resources dr. schluttig gmbh (8056069) - ondansetronhydrochlorid-dihydrat - injektionslösung - teil 1 - injektionslösung; ondansetronhydrochlorid-dihydrat (23418) 10 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pharma resources dr. schluttig gmbh (8056069) - ondansetronhydrochlorid-dihydrat - injektionslösung - teil 1 - injektionslösung; ondansetronhydrochlorid-dihydrat (23418) 5 milligramm